{"id":20576,"date":"2023-03-27T16:26:00","date_gmt":"2023-03-27T08:26:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20576"},"modified":"2025-01-06T16:30:51","modified_gmt":"2025-01-06T08:30:51","slug":"everest-medicines-receives-280-million-from-gileads-immunomedics-following-partnership-cancellation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20576","title":{"rendered":"Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952<\/a>) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD<\/a>). This payment is in relation to the cancellation of a partnership established in 2019, which was focused on the development of Trodelvy (sacituzumab govitecan) in certain Asian territories. Additionally, Everest has been reimbursed USD 34 million for expenses associated with the transition of Trodelvy.<\/p>\n\n\n\n

In April 2019, Everest secured the rights to develop Immunomedics’ Trodelvy in Asian markets through a deal valued at nearly USD 800 million. This initial agreement included an upfront payment of USD 65 million, with an additional USD 60 million contingent upon US FDA approval for Trodelvy in the treatment of metastatic triple-negative breast cancer, which Immunomedics successfully achieved in 2021.<\/p>\n\n\n\n

The landscape shifted following Gilead’s acquisition of Immunomedics for USD 21 billion in October 2020. The 2019 partnership was officially cancelled in August 2022, with Gilead and Immunomedics committing to a total compensation package that includes the USD 280 million upfront payment and an additional USD 175 million in future milestone-related payouts.<\/p>\n\n\n\n

This substantial payment enhances Everest’s financial position, providing the company with approximately USD 430 million in pro forma cash. This capital will bolster Everest’s ongoing pipeline development, with key milestones expected in core therapeutic areas such as renal disease, an mRNA platform, and infectious diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,126,226,1164,3014,1025],"class_list":["post-20576","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-everest-medicines","tag-gilead-sciences","tag-hkg-1952","tag-immunomedics","tag-nasdaq-gild"],"yoast_head":"\nEverest Medicines Receives $280 Million from Gilead's Immunomedics Following Partnership Cancellation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a partnership established in 2019, which was focused on the development of Trodelvy (sacituzumab govitecan) in certain Asian territories. Additionally, Everest has been reimbursed USD 34 million for expenses associated with the transition of Trodelvy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20576\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Receives $280 Million from Gilead's Immunomedics Following Partnership Cancellation\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20576\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T08:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T08:30:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20576#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20576\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation\",\"datePublished\":\"2023-03-27T08:26:00+00:00\",\"dateModified\":\"2025-01-06T08:30:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20576\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Everest Medicines\",\"Gilead Sciences\",\"HKG: 1952\",\"Immunomedics\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20576#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20576\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20576\",\"name\":\"Everest Medicines Receives $280 Million from Gilead's Immunomedics Following Partnership Cancellation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-27T08:26:00+00:00\",\"dateModified\":\"2025-01-06T08:30:51+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a partnership established in 2019, which was focused on the development of Trodelvy (sacituzumab govitecan) in certain Asian territories. Additionally, Everest has been reimbursed USD 34 million for expenses associated with the transition of Trodelvy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20576#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20576\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20576#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Receives $280 Million from Gilead's Immunomedics Following Partnership Cancellation - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a partnership established in 2019, which was focused on the development of Trodelvy (sacituzumab govitecan) in certain Asian territories. Additionally, Everest has been reimbursed USD 34 million for expenses associated with the transition of Trodelvy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20576","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Receives $280 Million from Gilead's Immunomedics Following Partnership Cancellation","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20576","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-27T08:26:00+00:00","article_modified_time":"2025-01-06T08:30:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20576#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20576"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation","datePublished":"2023-03-27T08:26:00+00:00","dateModified":"2025-01-06T08:30:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20576"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Everest Medicines","Gilead Sciences","HKG: 1952","Immunomedics","NASDAQ: GILD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20576#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20576","url":"https:\/\/flcube.com\/?p=20576","name":"Everest Medicines Receives $280 Million from Gilead's Immunomedics Following Partnership Cancellation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-27T08:26:00+00:00","dateModified":"2025-01-06T08:30:51+00:00","description":"China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a partnership established in 2019, which was focused on the development of Trodelvy (sacituzumab govitecan) in certain Asian territories. Additionally, Everest has been reimbursed USD 34 million for expenses associated with the transition of Trodelvy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20576#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20576"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20576#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20576"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20576\/revisions"}],"predecessor-version":[{"id":20577,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20576\/revisions\/20577"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}